Use of Evolocumab in Familial Hyperlipidemia With Isolated Heart Transplant.
familial lipidemia
heart transplant
hypercholesterolemia
lipid-lowering therapy
simultaneous heart-liver transplant
Journal
JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292
Informations de publication
Date de publication:
07 Aug 2024
07 Aug 2024
Historique:
received:
10
04
2024
revised:
30
05
2024
accepted:
31
05
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
epublish
Résumé
We describe a novel use of evolocumab for successful postoperative lipid control in a patient with familial hyperlipidemia who underwent isolated heart transplantation. We believe that this case carries valuable lessons regarding post-transplant proprotein convertase subtilisin kexin 9 inhibitor use with implications for the future of combined organ allocation and transplantation waitlist times.
Identifiants
pubmed: 39157565
doi: 10.1016/j.jaccas.2024.102426
pii: S2666-0849(24)00219-5
pmc: PMC11328786
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
102426Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.